Reata Pharmaceuticals (NASDAQ:RETA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “

A number of other equities analysts also recently issued reports on RETA. BidaskClub downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Robert W. Baird restated a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a research note on Tuesday, October 24th. ValuEngine downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research note on Thursday, December 14th. Three analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $54.71.

Shares of Reata Pharmaceuticals (RETA) opened at $26.46 on Wednesday. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18. Reata Pharmaceuticals has a 52 week low of $19.48 and a 52 week high of $40.88. The company has a market capitalization of $675.28, a price-to-earnings ratio of -17.29 and a beta of -2.52.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to analyst estimates of $12.54 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities research analysts anticipate that Reata Pharmaceuticals will post -1.91 earnings per share for the current year.

In related news, Director R Kent Mcgaughy, Jr. bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 27th. The shares were bought at an average cost of $25.83 per share, with a total value of $387,450.00. Following the acquisition, the director now owns 25,004 shares in the company, valued at $645,853.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder James W. Traweek, Jr. bought 17,000 shares of the firm’s stock in a transaction that occurred on Saturday, December 29th. The stock was bought at an average cost of $28.47 per share, for a total transaction of $483,990.00. Following the completion of the acquisition, the insider now owns 35 shares in the company, valued at approximately $996.45. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 413,813 shares of company stock worth $10,453,354. Company insiders own 44.00% of the company’s stock.

A number of institutional investors have recently made changes to their positions in RETA. Nationwide Fund Advisors raised its holdings in Reata Pharmaceuticals by 38.1% in the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock worth $138,000 after purchasing an additional 1,206 shares during the period. Wells Fargo & Company MN raised its holdings in Reata Pharmaceuticals by 37.4% in the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock worth $176,000 after purchasing an additional 1,521 shares during the period. First Allied Advisory Services Inc. bought a new position in Reata Pharmaceuticals in the 3rd quarter worth $203,000. The Manufacturers Life Insurance Company raised its holdings in Reata Pharmaceuticals by 102.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock worth $233,000 after purchasing an additional 3,715 shares during the period. Finally, American International Group Inc. raised its holdings in Reata Pharmaceuticals by 42.5% in the 3rd quarter. American International Group Inc. now owns 7,528 shares of the company’s stock worth $234,000 after purchasing an additional 2,247 shares during the period. 29.52% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/07/reata-pharmaceuticals-reta-rating-lowered-to-sell-at-zacks-investment-research.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.